Ekso Bionics Holdings Inc (EKSO) Stock AnalysisEKSOStock AnalysisEkso Bionics Holdings Inc

Ekso Bionics Holdings, Inc. designs, develops, and markets exoskeleton products. Its exoskeleton technology serves people with physical disabilities or impairments in both physical rehabilitation and mobility. It operates as one segment with two markets: Enterprise Health and Personal Health. Its products include EksoNR, which is a wearable robotic exoskeleton designed for a rehabilitation setting; Ekso Indego Therapy is a modular, adjustable, lightweight, lower limb-powered exoskeleton; Ekso Indego Personal is a lower limb orthosis; Ekso Nomad is a power Knee Ankle Foot Orthosis, and Ekso EVO is a wearable upper body exoskeleton. It enables individuals with neurological conditions affecting gait, including acquired brain injury (ABI) and spinal cord injury (SCI), to rehabilitate, stand and walk again. Additionally, the devices assist people with a variety of upper extremity disabilities and enable industrial employees to perform challenging repetitive tasks for extended periods. It operates in the Healthcare sector (GENERAL INDUSTRIAL MACHINERY & EQUIPMENT, NEC industry).

EKSO is not a good buy right now for a beginner, long-term investor with $50,000-$100,000 to deploy. The stock has short-term technical strength, but the business fundamentals are weak, there is no fresh news catalyst, no supportive options activity, and no strong institutional or insider buying signal. I would not buy this name now; the better call is to avoid it and wait for a materially stronger fundamental setup.

1 analysts cover EKSO: 1 rate it Buy, 0 Hold and 0 Sell.